Product Description
Astellas Pharma was developing asp-4901, an oral PDE9 inhibitor, for the treatment of benign prostatic hyperplasia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02038868)
Mechanisms of Action: PDE9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostatic Hyperplasia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
4901-CL-0201 | P2 |
Completed |
Prostatic Hyperplasia |
2014-04-04 |
24% |